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Abstract
Background: This study aimed at reseaching the immune effect of porcine circovirus type 2 (PCV2) DNA vaccine
containing CpG motif on mice.
Methods: A total of 40 6-week-old female BALB/c mice were randomly divided into four groups which were
immunized by 18CpG-pVAX1-ORF2, pVAX1-ORF2, pVAX1 and PBS, respectively, and immunized again 2 weeks later.
All mice were challenged with 0.2 mL PCV2 cells virulent strain SD (106.0 TCID50/mL) after 4 weeks. Average daily
gain, blood antibody levels, microscopic changes and viremia were detected to estimate the effect of DNA vaccine.
Results and Discussion: The results showed that compared to those of the control mice, groups immunized with
pVAX1-ORF2 and 18CpG-pVAX1-ORF2 could induce PCV2-specific antibodies. The PCV2-specific antibodies level of
18 CpG-pVAX1-ORF2 groups was higher significantly than other groups and decreased slowly along with time.
There was no distinct pathological damage and viremia occurring in mice that inoculated with CpG motif DNA
vaccines. The results demonstrated that the DNA vaccine containing 18 CpG could build up resistibility immunity
and reduce immune organ damage on mice.
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Background
Porcine circovirus (PCV) is a small, nonenveloped, icosa-
hedral virus containing a circular single-stranded DNA
genome, which is assigned to the Circoviridae family. PCV
comprises with two genotypes, which are non-pathogenic
PCV1 and pathogenic PCV2 [1]. The former exist widely
in PK-15 cells, and the latter is closely related with post-
weaning multisystemic wasting syndrome (PMWS) [2],
which mainly infect weaned pigs and fattening pigs. Now-
adays, porcine circovirus type 2 (PCV2) has become one
of the most important pathogens affecting the swine in-
dustry worldwide [3]. PCV2 contains at least two major
open reading frames (ORFs). ORF1 encodes the
replication proteins (Rep and Rep’) which involved in virus
replication, and ORF2 encodes the capsid proteins (Cap)
were found to be immunogenic which made them suitable
for vaccine development [4].
Currently, PCV2 vaccination is still an important
method to combat porcine circovirus diseases (PCVD).
At present, chimeric viruses, subunit vaccines, recom-
binant vaccines, genetic engineering vaccines and other
kind of vaccines were researched at home and abroad.
However, the most successful vaccine candidates were
those based on the induction of an active immune re-
sponse against the capsid protein of PCV2 [5–7].
Some domestic and international reports have showed
that CpG motifs have the effect of immunostimulation as
an immune adjuvant [8, 9]. CpG motifs can activate the
immune system by enhancing the antigen presentation
capacity of APC. The current research on CpG as immune
adjuvant was mainly focused on the mouse and human
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disease. Based on the earlier research in the authors ‘la-
boratory (Cheng KH, “Study on Series of DNA Vaccines
Against Porcine Circovirus Type 2[D],”[master’s thesis
QingDao Agricultural University, 2009]), we first reported
the CpG motifs as an adjuvant insert to the PCV2 DNA
vaccine that could boost immunity in pigs [10].
Our research and other research had showed that
mouse could be infected by PCV2 and used as a PCV2
infected experimental model [11, 12]. In this study,we
evaluate immune effect of PCV2 DNA vaccine with CpG
motif on mice using the best CpG motif from our earlier
research [10], which can provide a great prospect for
preventing and controlling PCVD,in order to give candi-
date vaccine evaluation model.
Methods
Viruses and vaccine
The titer of PCV2 strain SD on PK-15 cells (DQ478947)
was 106.0 TCID50/ml. PCV2 strain SD,DNA vaccine plas-
mid 18CpG-pVAX1-ORF2,plasmids pVAX1-ORF2 and
pVAX1 were constructed by Cheng Kaihui and saved by
Shandong Key Laboratory of Animal Disease Control &
Breeding. PCV2 strain SD was also preserved in Chinese
bacterium Preservation Center (CGMCC NO.5774).
Animal vaccination
Six-week old female BALB/c mice (Shandong province
Experimental Animal Centre, China) were divided ran-
domly into four groups (10 mice/group), which were im-
munized intramuscular injection in legs by 18CpG-
pVAX1-ORF2, pVAX1-ORF2, pVAX1 or PBS, respect-
ively, and immunized again after 2 weeks (Table 1). All
mice were challenged intramuscularly with 0.2 mL
PCV2 cells virulent strain SD (106.0 TCID50/mL) after
4 weeks. Average daily gain was recorded everyday dur-
ing the experiment. All mice experimental procedures
were performed in accordance with the Regulations for
the Administration of Affairs Concerning Experimental
Animals approved by the State Council of People’s
Republic of China.
Physical signs studies
The change of body weight was recorded at the time of
vaccinations, and before PCV2 cells virulent strain chal-
lenge. Average daily gain was calculated to evaluate the
vaccine effection.
Assay of mice blood antibody levels
The blood samples was collected at the time of vaccina-
tions, 2 weekly intervals during immunity period and
weekly after challenge until necropsy, respectively. The
serum were separated and detected blood antibody levels
with PCV2-dCap-ELISA kit (Tianjin ringpu biotechnol-
ogy Limited by Share Ltd) according to the manufac-
turer’s directions. The positive cutoff was set at S/P ≥
0.25 when S/P = (OD450 of sample - OD450 mean of
negative control)/(OD450 mean of positive control -
OD450 mean of negative control).
Pathological and histopathology studies
The mice were euthanized at 3 weeks after challenge and
samples from the lung, spleen and liver were fixed in 10 %
neutral-buffered formalin solution, and were sectioned
and stained with hematoxylin and eosin (HE). Microscopic
changes were determined by comparing the tissues of the
challenged mice with those of the control-groups.
Assay of PCV2 distribution by Real-time PCR
Real-time PCR was used to detect the virus in the neck
muscles, heart, liver, spleen, lung, kidney and blood. One
pair of polymerase chain reaction (PCR) primers D1 5′-
TTACCGGCGCACTTCGGCAG -3′ and D2 5′-
ACTCCGTTGTCCCTGAGAT -3′ were designed using
computer software (Primer Premier 5.0) according to
the published sequence of the PCV2 in GenBank
(DQ478947) to establish a fluorescent quantitative PCR
assay for the detection of PCV2 (404 bp). The amplifica-
tion was carried out in a 25 μL reaction containing
1 μM of each forward and reverse primer, 12.5 μL of
SYBR Green I Mix (TaKaRa), 2 μL DNA templates, and
ddH2O up to 25 μL. The PCR conditions were as fol-
lows: 95 °C for 10 min, followed by 30 cycles of amplifi-
cation at 95 °C for 10 s, and 55°Cfor 10 s [13]. The
assays were repeated at least three times, with each ex-
periment performed in triplicate.
Statistical analysis
All data were performed using SPSS 15.0 software (SPSS
Inc., Chicago, IL, USA). Statistical analyses were ana-
lyzed by two-way analysis of variance (ANOVA)
followed by Tukey’s post hoctest, respectively. Differ-
ences were considered significance at p < 0.05.





I(Control) PBS 0.2 mL
II pVAX1 0.2 mL(Plasmid concentration
500 μg/mL)
III pVAX1-ORF2 0.2 mL(Plasmid concentration
500 μg/mL)
IV 18CpG-pVAX1-ORF2 0.2 mL(Plasmid concentration
500 μg/mL)
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Result
Average daily gain (ADG)
Body weight was recorded at day 1 and 4 week, ADG of
every mouse was calculated and statistical analyses were
performed. The result showed that compared to the
control mice (group I),there was no significant difference
among groups (p ≥ 0.05), and the weight gain was not al-
tered by vaccination in mice.
Assay of blood antibody detection
Porcine circovirus type 2 (PCV2)-antibody responses
monitored by PCV2-ORF2 protein enzyme-linked im-
munosorbent assay. The antibody level of group III and
IV was rised gradually after first immunization, and
group IV showed an obvious rise after secondary
immunization, while group III rised within a narrow
range. However, the antibody of group IV was still up to
0.3097 at 4 week after secondary immunization, which
was positive. Thus, the immune effect of DNA vaccine
containing 18 CpG was better than other groups
throughout the time after vaccination. After challenge
with PCV2 strain SD, the antibody level of the four
groups was all rised due to the anamnestic response in
the vaccinated groups, and the highest level was
appeared at 1 week after challenge. The antibody level of
group IV was higher significantly than other groups
(p < 0.05), and decreased slowly along with time
(Fig. 1). The results of mice blood antibody detection
(S/P) was showed in Table 2.
Clinical observation and pathological changes
All mice of group I and II becoming lean, almost emaci-
ated and displayed splenomegaly, No obvious clinical
signs and gross lesions were observed in the vaccinated
group mice of group III and IV.
The alveolar walls thicked and inflammatory cells infil-
trated in lung bronchia were showed in mice of group I
(Fig. 2a). Interstitial pneumonia, and congestion were
observed in alveolar interlobular interval and infiltration
with inflammatory cells (Fig. 2b) while the hepatocyte
showed slight atrophy and hemorrhage (Fig. 2j) in group
II mice. A few of inflammatory cells were observed in al-
veoli of group III (Fig. 2c). Degenerative necrosis in kid-
ney tubules and wider congestion in the glomeruli were
observed in group I-III (Fig. 2e, f, g). Typical slight vacu-
oles granular degeneration was observed in hepatocyte
of group I (Fig. 2i) and III (Fig. 2k), respectively. No ob-
vious unusual changes were observed in lungs, kidney
and liver of group IV (Fig. 2d, h, l). The result showed
that the DNA vaccine containing 18 CpG could provide
an effective immune protection.
Quantitative analysis of PCV2 expression in tissues and blood
The PCV2 contents in blood and different tissues were
calculated at 1, 2 and 3 weeks after injection (Table 3,
Fig. 1 Serum antibody level after immunization in mice
Table 2 Serum antibody level after immunization in mice (S/P)
Groups Pre-immune
blood


















I 0.1507 0.1510 0.1601 0.1500 0.2329 0.2206 0.1993
II 0.1507 0.1628 0.2052 0.1862 0.4249 0.3084 0.2426
III 0.1507 0.2576 0.3003 0.2417 0.5928 0.4267 0.3223
IV 0.1507 0.3127 0.4340 0.3097 0.6754 0.5795 0.5186
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Fig. 3). The results showed that PCV2 were not detected
in the position of injection which is neck muscles. Atthe
first week after injection, while the PCV2 contents of
groups III and IV were less than groups I and II (p <
0.05). PCV2 were not detected in the tissues and blood
of group IV at 3 weeks after injection, while the liver,
spleen, kidney and blood have a few PCV2, which ex-
plained the virus was not eliminated completely. In
addition, the amount of PCV2 in spleen was the highest
in all the tissues and blood (Fig. 2).
Discussions
PCV2, the primary causative agent of PMWS, PRDC,
mainly infected the weaned piglets (Allan et al., 1998),
resulting in substantial economic losses to the pig indus-
try. At present, there were not good drugs to treat with
the diseases caused by PCV2. Thus, vaccine immunization
has become a fundamental means and measures to pre-
vent PCV2.
Nucleic acid vaccine is one of the hot spot of PCV2
vaccine researches. DNA vaccines may be capable of in-
ducing immunity regardless of maternally derived anti-
bodies [14, 15] and they have induced protective cellular
and humoral immunity in preclinical models of infec-
tious diseases. PCV2 Nucleic acid vaccine was first re-
ported by Kamstrup [16], they developed and
investigated the potential of DNA vaccination approach
to against PCV2. Mice were vaccinated three times by
gene gun and all mice responded serologically by raising
antibodies against PCV2. They found that vaccination
based on DNA might offer opportunities for vaccination
of piglets against PCV2.
However, DNA vaccine applications are limited due
to the problems related to delivery, species of the im-
munized animals and degradation of plasmid DNA.
To compensate for these limitations, numerous stud-
ies have explored methods to improve immune re-
sponses induced by DNA immunization by optimizing
plasmid design, vaccine delivery systems and adju-
vants [17]. Adjuvants are of particular interest
Fig. 2 Histopathological changes in the lungs (A-D), kidney (E-H) and liver (I-L) of mice infected by PCV2 (HE). Mice of group I (PBS) showed
alveolar walls were thick and inflammatory cells were in the lung bronchia (a). Mice of group II (pVAX1) showed interstitial pneumonia, and
congestion was observed in alveolar interlobular interval and infiltration with inflammatory cells (b). A few of inflammatory cells were observed in
alveoli of group III (pVAX1-ORF2) (c). Wider congestion in the glomeruli was observed in group I-III, and degenerative necrosis in kidney tubules
were observed in group I and II (e, f). The typical or slight vacuoles granular degeneration was observed in hepatocyte of group I or III,
respectively (i, k). The hepatocyte of group II showed slight atrophy (j). No obvious unusual changes were observed in lungs, liver and kidney of
group IV (d, h, l). The scale bar is 100 mm
Table 3 The testing result of PCV2 in the organs of mice
days Groups heart liver spleen lung renal muscle blood
7d I + + + + + + +
II + + + + + + +
III + + + - + + +
IV + + + + + - +
14d I + + + + + + +
II + + + + + + +
III + + + - + - +
IV + - + - + - +
21d I + + + + + + +
II + + + + + + +
III - + + - + - +
IV - - - - - - -
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because they may enhance DNA delivery and increase
the magnitude and duration of plasmid DNA expres-
sion [18]. Guo (2015) reported the enhancement of
the immunogenicity of porcine circovirus type 2 DNA
vaccines by using a recombinant plasmid co-
expressing capsid protein and porcine interleukin-6 in
mice. Dong [19] found that the mice co-inoculated
with pVAX-PCV2-ORF2 plus pVAX-pIL-15 have
higher humoral and cellular immune responses than
the others. In addition, DNA plasmid bearing PCV2
ORF2 gene has a protective effect against challenge
with PCV2 in mice which could be promoted with
Fig. 3 The distribution of virus in different organizations of different periods
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the utilization of pIL-15.Fu [20] evaluated three adju-
vants Ubiquitin (ub), the peptide binding truncated
C-terminal portion of heat shock protein 70 (hsp70c)
and interleukin-2 (IL-2) in PCV2 DNA vaccine, they
found that ub is a superior adjuvant for PCV2 DNA
vaccination than the hsp70c and IL-2 molecules.
Chen [21] evaluated two recombinant plasmids con-
taining the ORF2 gene of porcine circovirus type 2
(PCV2) with or without porcine interleukin-18 (IL-18)
and found that the plasmid pBudCE4.1-ORF2/IL18
may be an effective approach for increasing the im-
munogenicity of PCV2 DNA vaccine.
Our previous research demonstrated that CpG motifs
as an adjuvant could boost the humoral and cellular im-
munity of pigs to against PCV2, especially in terms of
cellular immunity [10]. This study evaluated the adju-
vant of CpG motifs to PCV2 DNA vaccine and mainly
detected the serum antibody levels in mice by ELISA.
The results showed that the antibody levels of immune
groups were increased, especially the nucleic acid vac-
cine containing 18 CpG, kept at a higher level through-
out the immunization and decreased slowly, after
challenge, it increased rapidly and could maintain a lon-
ger time.
The result of quantitative real-time PCR showed that
PCV2 was replicated in the tissues of mice, while it was
eliminated gradually in immune groups. Moreover, the
content of PVC2 in spleen of all the tissues was the
highest. The result of autopsy declared obvious lesions
were appeared in group I and II, and minimal lesion was
appeared in group III. No obvious unusual changes were
observed in group IV.
Conclusions
In conclusion, the nucleic acid vaccine containing 18
CpG can build up resistibility immunity and reduce im-
mune organ damage on mice. which has a wide prospect
for preventing and controlling PCV2 infection.
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